Effects of Serelaxin in Patients with Acute Heart Failure

Marco Metra1, John R Teerlink1, Gad Cotter1

  • 1From Cardiology, Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia, Brescia (M.M.), Centro Cardiologico Universitario di Ferrara, University of Ferrara, Ferrara (R.F.), and Maria Cecilia Hospital, GVM Care and Research, Cotignola (R.F.) - all in Italy; the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), and the Division of Cardiology, University of California, San Diego, La Jolla (B.H.G.) - all in California; Momentum Research (G.C., B.A.D.) and the Division of Cardiology, Duke University School of Medicine (G.M.F.), Durham, and the University of North Carolina, Chapel Hill (K.F.A.) - all in North Carolina; the School of Medicine, University of Cyprus, Nicosia, Cyprus (G.F.); the School of Medicine, National and Kapodistrian University of Athens, Athens (G.F.); the Department of Emergency Medicine, Indiana University School of Medicine, and the Regenstrief Institute, Indianapolis (P.S.P.); the Department of Heart Diseases, Medical University, Military Hospital, Wrocław (P.P.), and Instytut Kardiologii, Warsaw (J.S.) - both in Poland; University of Groningen, Groningen, the Netherlands (A.A.V.); the Department of Internal Medicine and Cardiology, German Center for Cardiovascular Research partner site Berlin (S.D.A., B.P.), and Berlin Institute of Health Center for Regenerative Therapies (S.D.A.), Charité Universitätsmedizin Berlin-Campus Virchow Klinikum, Berlin, and Saarland University, Universitätsklinikum des Saarlandes Homburg, Homburg (M.B.) - all in Germany; the Coronary Care and Emergency Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (A.A.-M.); Hospital Clínico de la Fuerza Aérea de Chile, Las Condes, Chile (P.A.); the Heart Transplantation Department, Heart Institute (InCor), University of São Paulo, and Hospital Israelita Albert Einstein, São Paulo (F.B.); Sanatorio de la Trinidad Mitre, Buenos Aires (G.B.); the Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow (J.G.F.C.), National Heart and Lung Institute, Imperial College, London (J.G.F.C.), and the Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Biomedical Research Centre, Glenfield Hospital, Leicester (I.S.) - all in the United Kingdom; Cardiology Department, Hôpital Lariboisière and Université de Paris, Paris (A.C.-S.); Complejo Hospitalario Universitario A Coruña, Universidade da Coruña, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, La Coruña, Spain (M.G.C.-L.); Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (M.D.); Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Colombia (L.E.E.); Heart Institute, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem (S.G.); National Cardiovascular Institute, Bratislava, Slovakia (E.G.); Medical University of Sofia, Tzaritza Ioanna University Hospital, Sofia, Bulgaria (A.G.); the Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen (L.K.); Internal Medicine-Cardiology, Internal Medicine Department, Hospital Nacional Arzobispo Loayza, Lima, Peru (J.L.-O.); Wayne State University School of Medicine and Cardiovascular Research Institute, Detroit (P.D.L.); the School of Medicine and Medical Sciences and St. Vincent's University Hospital, University College Dublin, Dublin (K.M.); the Department of Internal Medicine, University of Witwatersrand, Johannesburg (P.M.); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); the Department of Cardiology and Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel (C.M.), and Novartis Pharma (T.H., T.S., P.S., C.G.), Basel, Switzerland; CINTESIS, Porto University Medical School, São João Medical Center, Porto, Portugal (J.S.-C.); University Hospital Brno and Medical Faculty Masaryk University, Brno, Czech Republic (J.Š.); University Hasselt, Hasselt, Belgium (W.V.M.); the Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria (D.L.); the Institute of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden (G.W.); Dokuz Eylül University, Faculty of Medicine, Department of Cardiology, Izmir, Turkey (M.B.Y.); and Novartis Pharmaceuticals, East Hanover, NJ (N.H., T.H., T.A.H., S.V.S.).

Abstract

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
888
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
473
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720